Eidelman Virant Capital Cuts Stake in CVS Health Co. (NYSE:CVS)

Eidelman Virant Capital lowered its position in shares of CVS Health Co. (NYSE:CVSGet Rating) by 50.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,425 shares of the pharmacy operator’s stock after selling 19,430 shares during the period. CVS Health comprises approximately 1.1% of Eidelman Virant Capital’s holdings, making the stock its 26th largest holding. Eidelman Virant Capital’s holdings in CVS Health were worth $1,966,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in CVS. West Bancorporation Inc. purchased a new position in shares of CVS Health during the fourth quarter valued at $25,000. Claremont Financial Group Inc. purchased a new position in shares of CVS Health during the fourth quarter valued at $26,000. Stuart Chaussee & Associates Inc. increased its stake in shares of CVS Health by 123.0% during the first quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock valued at $31,000 after buying an additional 171 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of CVS Health by 125.7% during the fourth quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock valued at $33,000 after buying an additional 176 shares during the period. Finally, Steph & Co. grew its stake in CVS Health by 138.7% in the fourth quarter. Steph & Co. now owns 358 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 208 shares during the last quarter. Hedge funds and other institutional investors own 78.00% of the company’s stock.

CVS has been the topic of several analyst reports. StockNews.com initiated coverage on CVS Health in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on CVS Health from $110.00 to $113.00 in a research note on Thursday, May 5th. Loop Capital initiated coverage on CVS Health in a research note on Thursday, June 16th. They issued a “buy” rating and a $120.00 target price on the stock. Sanford C. Bernstein lowered CVS Health from an “outperform” rating to a “market perform” rating and cut their target price for the company from $122.00 to $112.00 in a research note on Thursday, May 26th. Finally, Tigress Financial raised their price target on CVS Health from $122.00 to $125.00 in a report on Thursday, April 7th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $116.05.

In other news, EVP Prem S. Shah sold 16,954 shares of the business’s stock in a transaction that occurred on Friday, April 8th. The stock was sold at an average price of $105.00, for a total value of $1,780,170.00. Following the completion of the sale, the executive vice president now directly owns 43,453 shares in the company, valued at $4,562,565. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Prem S. Shah sold 5,346 shares of the business’s stock in a transaction that occurred on Wednesday, March 30th. The shares were sold at an average price of $104.70, for a total value of $559,726.20. The disclosure for this sale can be found here. Insiders sold 77,659 shares of company stock valued at $7,882,993 over the last three months. 0.69% of the stock is currently owned by corporate insiders.

Shares of CVS Health stock traded up $0.51 on Wednesday, reaching $91.59. 30,543 shares of the stock were exchanged, compared to its average volume of 4,403,811. CVS Health Co. has a twelve month low of $79.33 and a twelve month high of $111.25. The firm has a market capitalization of $120.10 billion, a price-to-earnings ratio of 15.13, a PEG ratio of 1.40 and a beta of 0.78. The business has a 50 day moving average price of $97.35 and a two-hundred day moving average price of $101.49. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 0.70.

CVS Health (NYSE:CVSGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.08. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. The company had revenue of $76.83 billion during the quarter, compared to the consensus estimate of $75.30 billion. During the same period in the previous year, the company posted $2.04 earnings per share. CVS Health’s revenue for the quarter was up 11.2% on a year-over-year basis. Research analysts forecast that CVS Health Co. will post 8.33 EPS for the current year.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

See Also

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSGet Rating).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.